Accredited Investor Exclusive

300% to 400% Potential
High Value Inflection Point in 2025

Our former ex-FDA experts, based on their experience, and vendor price quotes, believe The Gene Facelift™ has enough funding to potentially file our FDA IND in 2025 and start our First-in-Human Phase 1 study.

Is This The Fountain of Youth?

What if there were an actual fountain of youth? What if it delivered a new, true, non-invasive “age reversing” solution for wrinkles, sagging, under-eye bags and circles, baldness, and other high-anxiety skin issues? Introducing The Gene Facelift™. If approved by the FDA, this is the easiest and most effective “Yes!” in anti-aging skin therapy to date for both doctors and patients.

No Pain No Gain

Toxins paralyze. Fillers plump. Other technologies ‘fry’ the skin. And most current options are invasive and painful. The Gene Facelift™ is a non-invasive topical treatment of non-viral DNA. The topical application allows for ease of access and low patient burden.

The GENIE Therapeutics
Multi-Drug Platform Technology Solution

Funded in part by the National Institutes of Health (NIH), The Gene Facelift™ is the first patented drug candidate to potentially regenerate aged, thin skin, reducing wrinkles, sagging, and other aesthetic and high-anxiety concerns.

Non-Invasive

The Gene Facelift™ is a non-invasive topical treatment of non-viral DNA. The topical application allows for ease of access and low patient burden.

Triples Skin Thickness

Preclinical data shows The Gene Facelift™ rapidly triples skin thickness, regenerating collagen, elastin, and skin stem cells.

Highly Profitable

The Gene Facelift™ is designed to be redosable, and could boost clinic profits by as much as 400% compared to current toxin treatments.

Gene Facelift regenerates and stimulates the skin’s stem cells, yielding 300% skin regrowth.

POTENTIAL RESULTS

The Future of Genetic Aesthetic Medicine: Invest in GENIE Therapeutics today for $1 per share.

Have questions? Call or text 302-405-2955

Key Investment Highlights

The Gene Facelift™ is a first-in-class drug candidate to potentially treat high-anxiety aesthetic issues such as wrinkles, under-eye bags and circles, baldness, rosacea, pigmentation, scarring, cellulite, and more.

Key Investment Highlights

Revolutionary Science

The company's patented gene therapy is the first of its kind potential solution that reverses skin aging, regenerates collagen, and significantly thickens skin - by a never before achieved 300% increase in preclinical studies - potentially eliminating wrinkles, under-eye bags, crow's feet, sagging skin, and other cosmetic concerns on the cellular level.

Platform Technology

GENIE Therapeutics has developed a multi-drug Platform Technology that may lead to multiple drug creations and launches from the same advanced DNA core, each one being a multibillion-dollar opportunity including wrinkles, hair loss, medical dermatology, and wound care.

Institutional Support

Supported with NIH research funding¹ and guided by the company's team of ex-FDA veteran employee insiders to help advance FDA approval process steps. It is important to note that approvals for aesthetic drugs are generally less tedious than other drugs. In fact, we are not aware of an aesthetic drug candidate that was never successfully approved.

Disrupting Our Way To A Potential $1+ Billion In Yearly Sales

Just three of the markets that GENIE Therapeutics is targeting (non-invasive aesthetics treatments, medical dermatology, and wound care) represent a total addressable market of $101 Billion.

Powerful Partnerships

Danaher, ranked #132 on the Fortune 500 and part of the S&P 100, is a shareholder in GENIE Therapeutics. The company has formed a strong licensing partnership with Danaher for future high-yield HyperGRO™ GMP drug manufacturing. Danaher is highly qualified to meet all FDA GMP and CMC manufacturing requirements.

Lower Barrier of Entry

Because The Gene Facelift™ is a topical aesthetic drug, the cost associated with potential FDA development and approval is estimated at ~$30 million, much lower than other drugs used systemically for diseases such as cancer or heart disease.

The Exit Potential

GENIE is uniquely positioned to execute against an extensive menu of full or partial potential exits. Each FDA milestone creates potential high demand for:

The Future of Genetic Aesthetic Medicine: Invest in GENIE Therapeutics today for $1 per share.

Have questions? Call or text 302-405-2955

Transforming Skin Health with our Platform of Non - Viral Gene Therapy

The DATA

GENIE’s Gene Facelift™ powers an unprecedented 300% increase in skin regeneration never previously scientifically achieved!

One topical treatment shows significant regeneration of new elastin, collagen, stem cells, and skin thickness. GNE-142 regenerated a 300% increase in skin thickness – never before seen molecular age reversal results. This breakthrough Platform, developed with Johns Hopkins and NIH funding, has blockbuster potential to create multiple drugs from the same advanced DNA core. With revolutionizing aesthetics, it can be used across all full-body aesthetic skin conditions.

Disrupting our way to a potential

$1+ billion in yearly sales

The GENIE multi-drug Platform Technology is capable of addressing numerous high-prevalence disease states within multiple billion-dollar markets.

Meet Our Expert Team

The GENIE team has extensive experience in aesthetics and dermatology, FDA regulatory approvals, and experience building businesses with exits.

Aaron Tabor, MD

Founder & CEO

Aaron Tabor, MD, is the Founder, Co-Inventor and CEO of GENIE Therapeutics. Dr. Tabor is a graduate of the The Johns Hopkins School of Medicine. He is the lead inventor of GENIE Therapeutics’ “genetic cosmetics” First-in-Class aesthetic drugs.

Joseph Pergolizzi, MD

Shareholder & Scientific Advisor

Joseph Pergolizzi, Jr., MD, is the prior Co-Director of Business Development for The Johns Hopkins Clinical Trials Unit (CTU). He is a former part-time Adjunct Assistant Professor at Johns Hopkins.

Anish Meta, MBA, MS

Shareholder & Advisor

Anish Mehta, a former VP of Allergan, is the founder and former CEO of Theramex, a $1 Billion global Women’s Health speciality pharmaceutical company.

Cassondra Todd

PRESIDENT

Cassondra Todd is an extraordinary marketer proven by an unparalleled track record of growing, directing and managing top-tier plastic surgery practices and providers in southern California. Her decades long series of successful

Bruce Schneider, MD

FDA Scientific Advisor

Ex-FDA Medical Officer employee (22+ years). Regulation of clinical trials of cellular and gene therapies including Aesthetic new drug applications. Graduate of Harvard Medical School. Prior Professor of Medicine at the Albert Einstein College of Medicine.

Benjamin Vali, MS, RAC

FDA Scientific Advisor

Ex-FDA employee (13+ years) in Regulatory Affairs with focus on Regulatory Science and Pharmaceutical Product Development. Performed regulatory reviews of pre-IND and IND submissions, NDAs, and BLAs with a focus on the statistical

Our Key Shareholders and NIH Research Funding

Johns Hopkins University

national institutes of health

danaher

The Future of Genetic Aesthetic Medicine: Invest in GENIE Therapeutics today for $1 per share.

Have questions? Call or text 302-405-2955

The GENIE roadmap & clinical pipeline

GENIE Therapeutics has a catalyst-rich pipeline powered by our multi-drug Platform Technology with numerous value drivers pending FDA guidance. We are positioned to deliver significant value creation through numerous programs with near-term inflection points. Our potential timeline to commercialization:

YEAR

01

  • Start preclinical studies with ex-FDA experts
  • Submit IND with multiple indications: wrinkles, skin tightening, and scar revision (GNE-142, GNE-143)
  • Generate preclinical data on hair loss (GNE-146, GNE-147)
  • GMP / CMC process initiation

02

  • Begin Phase 1/2 clinical studies on GNE-142, GNE-143
  • Submit IND on GNE-146, GNE-147

03 & 04

  • Phase 1/2 readout on GNE-142, GNE-143
  • Begin Phase 3 studies on GNE-142, GNE-143
  • Begin Phase 1/2 clinical studies on GNE-146, GNE-147

05

  • Submit BLA applications for GNE-142, GNE-143
  • Continue development and expansion of pipeline

GENIE Therapeutics Offering Details

OFFERING TYPE

Equity

MINIMUM INVESTMENT

$ 10,000

PRICE PER SHARE

$ 1.00

TARGET RAISE

$ 5M

VALUATION CAP

$ 100M

EXIT STRATEGIES

Acquisition. Partnering. IPO, & Out-Licensing

Join industry pioneer GENIE shareholders like Johns Hopkins and Danaher by investing in the new era of anti-aging skin regeneration and wound healing therapy.

Frequently Asked Questions

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

The Future of Genetic Aesthetic Medicine: Invest in GENIE Therapeutics today for $1 per share.

Have questions? Call or text 302-405-2955

Accredited Investor Exclusive

Invest In The First Gene Regeneration Therapy Yielding 300% Skin Regrowth

GENIE Therapeutics is pioneering aesthetic gene therapies. This breakthrough multi-drug Platform Technology, developed with Johns Hopkins and NIH funding, if FDA approved, has blockbuster potential.